Stada Says Strength of Russian Unit May Attract Bids

Stada Arzneimittel AG, the German generic-drug maker that spent more than 250 million euros ($331 million) on acquisitions last year, said it expects to draw takeover offers from rivals seeking to expand in Europe.

“In Europe, we have a sweet spot in Russia” and “we are doing a very good job” in businesses including consumer health care, Markus Metzger, the Bad Vilbel, Germany-based company’s director of investor relations, said yesterday at the JPMorgan Chase & Co. health-care conference in San Francisco. Companies that don’t have those businesses in Europe “may look at buying us,” he said.